Acquired disorders of platelet function

Coagulation tests predict bleeding after cardiopulmonary bypass

OBJECTIVE

To determine the accuracy of coagulation profile laboratory tests, thromboelastography, and Sonoclot (SCT) values for predicting microvascular bleeding after cardiopulmonary bypass (CPB).

DESIGN

A prospective, blinded trial.

SETTING

A large academic medical center.

PARTICIPANTS

Eighty-two adult patients undergoing elective cardiac surgery.

INTERVENTIONS

Ten minutes after CPB, thromboelastography, SCT, and coagulation profile tests (bleeding time, prothrombin time, activated partial thromboplastin time, fibrinogen, fibrin split products, platelet count, mean platelet volume, and platelet hematocrit) were determined from a whole blood sample taken from an existing arterial catheter. Patients were subjectively defined as "bleeders" or "non-bleeders" by blinded clinical observers. Preoperative baseline tests were also obtained.

MEASUREMENTS AND MAIN RESULTS

Thirty of the 82 patients (36.6%) were characterized as bleeders. Coagulation profile tests had the best correlation with intraoperative and postoperative blood loss. The specificity, sensitivity, and negative and positive predictive values were determined by receiver operating characteristic analysis, and the test values that differentiated normal from abnormal (bleeding) patients were determined. The coagulation profile laboratory tests had the greatest maximal sensitivity and specificity for predicting bleeding. These predictive values were outside the normal range for these laboratory tests. The thromboelastography values that produced maximal sensitivity and specificity were in the normal range for that test.

CONCLUSION

Contrary to previous studies, coagulation profile tests had the greatest sensitivity and specificity to differentiate patients with excessive bleeding (abnormal) from those without excessive bleeding (normal) after CPB. Therefore, these tests should be used to guide transfusion therapy in patients who have excessive bleeding after CPB.

Closure of a ventricular septal defect in a patient with von Willebrand disease

Few reports of open heart surgery being performed in patients with von Willebrand disease (vWD) have been documented. We describe herein the case of a 5-year-old girl with a ventricular septal defect (VSD) and vWD who underwent patch closure under cardiopulmonary bypass (CPB). The hematological parameters relating to vWD, namely, factor VIII, von Willebrand factor, and factor VIII-related antigen were monitored perioperatively. These laboratory findings were elevated after the termination of CPB, and consistently maintained within the normal range for 4 months postoperatively. The operation was successfully completed without the administration of factor VIII concentrates or homologous blood products.

Determination of normal versus abnormal activated partial thromboplastin time and prothrombin time after cardiopulmonary bypass

OBJECTIVE

The study's objective was to determine the prothrombin time (PT) and activated partial thromboplastin time (aPTT) values that differentiated normal from excessively bleeding patients immediately after cardiopulmonary bypass (CPB).

DESIGN

A prospective blinded study.

SETTING

A large academic medical center.

PARTICIPANTS

148 patients were studied.

INTERVENTIONS

aPTT and PT were determined by the hospital laboratory and the Biotrack 512 Coagulation Monitor (Ciba Corning Diagnostics, Medfield, MA) from an arterial whole blood sample obtained 10 minutes after protamine administration. Patients were subjectively and objectively defined as "bleeders" or "nonbleeders" with blinded observers.

MEASUREMENTS AND MAIN RESULTS

The specificity and sensitivity were determined by a receiver operating characteristic (ROC) analysis. Twenty-three of 148 patients (14.9%) were characterized as bleeders. The laboratory PT had a maximal specificity and sensitivity of 78% and 75%, respectively, at a value of 15.4 s, with a negative and positive predictive value of 93% and 33%, respectively. The maximal specificity and sensitivity of the laboratory aPTT was 64% and 76%, respectively, at a value of 46 s, with a negative and positive predictive value of 89% and 33%, respectively. aPTT and PT approached normal values after 12 hours in the intensive care unit.

CONCLUSION

The aPTT and PT values that produce the maximal sensitivity and specificity in the ROC analysis may be helpful to differentiate patients who are bleeding excessively from those patients who are not after CPB and to guide transfusion of blood products. New whole blood coagulation devices with rapid turn-around times had similar predictive value for bleeding tendency compared with standardized laboratory tests.

Platelet function defects associated with hemorrhage or thrombosis

Platelet dysfunction, especially acquired forms, is a common cause of hemorrhage, especially when associated with trauma or surgery. Although the hereditary platelet function defects are generally quite rare, hereditary storage pool disease is common enough to be suspected in an individual, usually a child, with characteristic historical and clinical findings. The acquired platelet function defects, especially those resulting from drugs, are common and should promptly be suspected in patients developing easy and spontaneous bruising, mild-to-moderate mucosal membrane hemorrhage, or unexplained bleeding associated with trauma or surgery. The template bleeding time is generally useful as a screening test of platelet function, but a normal template bleeding time, in the face of a suggestive history, suggestive clinical findings, or in a patient frankly bleeding, is not reliable, and platelet aggregation or lumiaggregation should be done in appropriate clinical situations. Also, prolongation of the template bleeding time is an unreliable predictor of clinical bleeding propensity. The mainstay of therapy for almost all these defects, if bleeding is significant, is the liberal infusion of appropriate numbers of platelet concentrates. The acquired platelet function defects should also be managed by attempts to treat or control the underlying disease, if possible, and offending drugs or potentially offending drugs should immediately be stopped.

Intraoperative measurement of activated partial thromboplastin time and prothrombin time by a portable laser photometer in patients following cardiopulmonary bypass

Intraoperative capabilities to rapidly assess coagulation status following cardiopulmonary bypass (CPB) may be of benefit in providing optimal hemostasis and transfusion management, because CPB causes abnormalities in coagulation that may increase morbidity and mortality. The Ciba Corning 512 coagulation monitor (Ciba Corning, Medfield, MA) is a compact and portable device that rapidly determines the prothrombin time (PT) and activated partial thromboplastin time (APTT) in whole blood samples. One hundred patients requiring CPB had APTT and PT determined in whole blood specimens by the 512 coagulation monitor and in plasma specimens by the hospital laboratory from the same arterial blood sample obtained after protamine administration. Correlation coefficients of 0.95 and 0.77 were obtained for the paired APTT and PT tests, respectively (P < 0.01). A bias of 12.6 seconds and 0.77 seconds was determined for the APTT and PT, respectively. The 95% confidence intervals of the bias of the APTT and PT were 9.7 seconds to 15.5 seconds and 0.3 seconds to 1.16 seconds, respectively. The 512 coagulation monitor provided APTT and PT results in less than 3 minutes compared to approximately 45 minutes for the hospital laboratory. A reduction in accuracy was associated with the 512 coagulation monitor PT and APTT when different sampling sites were used. The 512 coagulation monitor accuracy was not affected by a variation of hemoglobin concentration or platelet count between 6 and 12 gm/dL and 15 to 300 x 10(9)/L, respectively. In conclusion, the 512 coagulation monitor provided a rapid APTT and PT result, but the APTT was less accurate. Speeding access to hospital laboratory results would be even more efficacious and accurate.

Impaired conversion of exogenous arachidonic acid by platelets to thromboxane B2 and correction of that deficiency by interferon-alpha

In the course of an investigation of cyclooxygenase and 12-lipoxygenase activity in platelets of patients with myeloproliferative syndrome receiving treatment with interferon-alpha 2 patients showed unusual results which have not been reported so far. Both patients had thrombocytosis, in one case associated with polycythaemia. In platelets of both patients, a reduced conversion of exogenous 14C arachidonic acid to TXB2 was observed accompanied by a shift in conversion to PGE2 and 12-HETE in one patient and to 12-HETE alone in the other before therapy. These findings were paradoxically associated with evidence of enhanced platelet activation in vivo. Treatment of both patients with interferon-alpha resulted in reversal of the biochemical abnormalities and in clinical remission.